NEXOBRIEF
Your daily cheat code on finance, AI, current events & startups
Friday, April 3, 2026 | Issue #015 | 5 min read | No MBA Required
Good morning and happy Friday. We're taking a break from the war and the markets today. A weight loss pill just got approved in record time. A first-generation freshman just hit one of the greatest shots in March Madness history. And humans are headed to the moon for the first time in 50 years. Let's go.
⚡ BIG STORY
The Weight Loss Pill Just Changed. A Once-Daily Tablet Hits Pharmacies Monday.
The FDA approved Eli Lilly's new weight loss pill — called Foundayo — in just 50 days. That's 294 days faster than usual, and the fastest approval of a genuinely new type of drug since 2002. Prescriptions start Monday.
Here's why this is bigger than another drug approval. GLP-1 medications — the class that includes Ozempic and Wegovy — have already reshaped healthcare, reduced demand for knee replacements, and sent alcohol sales down. Until now, they all required injections. Foundayo is a once-daily pill with no food restrictions. You take it whenever. That removes one of the biggest barriers to adoption.
The numbers that matter:
Clinical trials showed average weight loss of 25 pounds — about 11% of body weight — over 16 months
Price with insurance: starts at $25/month. Cash price: $149–$349/month depending on dose
Medicare Part D coverage begins July — opening the market to tens of millions of older Americans
Fewer than 1 in 10 people who could benefit from a GLP-1 are currently taking one — that's the market Lilly is targeting
The Novo Nordisk rivalry heats up:
Novo Nordisk launched an oral Wegovy pill in January. Foundayo is the second. The battle between these two companies is going to define pharmaceutical investing for the next decade. Lilly has the manufacturing edge — Foundayo is a small molecule, easier and cheaper to make. Novo has the slight efficacy edge — their pill averages 2.2% better weight loss in trials. No one has done a head-to-head study yet. That race is coming.
NexoBrief take: The injectable era of GLP-1s changed healthcare. The pill era is going to change everything else — including how insurance is priced, how food companies market their products, and how hospitals plan capacity. This is a decade-long story, not a one-day story.
💰 MONEY MINUTE
The Final Four Is Set. Here's the Business of March Madness Nobody Talks About.
UConn. Illinois. Michigan. Arizona. Indianapolis. Saturday. The Final Four is set, and it's a genuinely great field — two #1 seeds, a #2 that came back from 19 down to beat Duke on a 35-foot buzzer-beater from freshman Braylon Mullins, and an Illinois program making its first Final Four in 21 years.
The basketball is great. The business is fascinating. March Madness is now the single largest sports betting event in the United States. DraftKings and FanDuel alone are processing hundreds of millions in tournament wagers. The NCAA just lost a court battle to stop DraftKings from using the phrase "March Madness" in its marketing. The platforms won. They almost always do.
The money behind the madness:
The NCAA tournament generates roughly $1 billion in TV rights revenue annually — CBS and TNT split coverage through 2032
Sports betting on the tournament is estimated at $3.1 billion wagered legally this year — a record
NIL has changed the economics on the court too: UConn's Alex Karaban and Michigan's Yaxel Lendeborg are among the highest-earning college athletes in the country
Michigan's "Fab Five" — Chris Webber, Jalen Rose, Juwan Howard, Jimmy King, and Ray Jackson — are reuniting for a special Final Four broadcast on truTV and HBO Max Saturday night
NexoBrief take: College basketball is the last truly amateur-feeling major sport in America — except it's not amateur anymore. NIL, the transfer portal, and billion-dollar broadcast deals have made it a full-blown industry. The Fab Five reunion is nostalgia. The betting numbers are the business.
🤖 AI TOOL OF THE DAY
Humans Are Heading to the Moon. Here's What AI Is Doing Up There.
Artemis II launched Wednesday night and the crew is now en route to the moon — 240,000 miles from Earth, on a nine-day mission that will make them the first humans to fly around the moon since Apollo 17 in December 1972. The mission is going well.
What's not getting enough coverage: this mission is running more AI than any crewed spaceflight in history. Machine learning systems are monitoring crew vitals in real time, managing power distribution, and flagging potential equipment failures before human operators would catch them. On the ground, AI is processing the telemetry data that used to require rooms full of engineers. NASA is, in effect, testing whether AI can be a reliable co-pilot in deep space.
Why this matters beyond the mission:
NASA's entire long-term plan runs through Artemis — a permanent lunar base, astronauts on Mars, a commercial lunar economy. If Artemis II goes well, it unlocks Artemis III, which is the actual Moon landing. That opens billions in contracts for Lockheed, Northrop, Boeing, and commercial players like Axiom Space and Vast. If AI performs well on this mission, it accelerates the case for AI-assisted autonomous spacecraft — a market that barely exists today.
Intuitive Machines and Astrobotic are building commercial lunar landers — Artemis validates the market for both
The "cislunar economy" — satellites, infrastructure, and resource extraction between Earth and the Moon — is projected to be a $100B+ market by 2040
SpaceX's Starship is the planned Artemis III lander — a successful NASA mission is good for Musk's IPO narrative even as he competes with NASA
NexoBrief take: Wednesday's launch is the first human spaceflight to the moon in 54 years. It's also the most consequential AI field test of 2026. The crew comes back in ten days. What we learn about AI in deep space will shape every mission that follows.
🚀 STARTUP SPOTLIGHT
Light-Based Internet Is Coming. A New Chip Could Change How Everything Connects.
A research team published findings this week that could quietly reshape wireless communications. Scientists developed a tiny chip packed with dozens of miniature lasers that transmits data using light rather than radio waves. In lab tests, it dramatically boosted speeds while cutting energy consumption — two problems that have defined wireless infrastructure for decades.
This matters because the world's wireless networks are hitting a wall. The explosion of AI, streaming, autonomous vehicles, and smart devices is consuming bandwidth faster than radio spectrum can keep up. Light-based wireless — called Li-Fi — has been theorized for years but has been held back by hardware that was too bulky and expensive. A chip-scale solution changes the equation.
The commercial path:
Short-range Li-Fi is already deployed in some hospitals and aircraft cabins — the new chip is about extending range and reducing cost
Data centers are the first major market — switching from radio to light for internal communications cuts energy bills and increases speed
The broader rollout depends on chipmakers scaling this, which is a 5–10 year story — but the research breakthrough is the milestone that starts the clock
NexoBrief take: Every decade has a connectivity breakthrough — fiber in the 90s, Wi-Fi in the 2000s, 4G in the 2010s, 5G in the 2020s. Light-based wireless might be the 2030s story. The chip that makes it possible just got a lot smaller.
🌍 CURRENT EVENTS
Ancient Bone Dice. A Sperm Whale Termite. And the World's Saddest Statistic.
Gambling is 12,000 years old:
Archaeologists published a study this week finding bone dice among Native American hunter-gatherers dating back 12,000 years — thousands of years before similar tools appeared anywhere else in the world. The dice produced random outcomes and were used for games of chance. Human beings have been gambling literally since before recorded history. DraftKings is just the latest version.
Scientists found a termite that looks like a sperm whale:
A new termite species was discovered in a South American rainforest canopy. It has an elongated head and concealed mandibles that make it look, unmistakably, like a tiny sperm whale. Its scientific name: Cryptotermes mobydicki. The discovery was published this week and is, objectively, one of the better things that happened in science this month.
The Alzheimer's-diet surprise:
A new study found that for people carrying high-risk APOE gene variants — which significantly raise Alzheimer's risk — eating more meat may actually lower cognitive decline compared to plant-heavy diets. It contradicts conventional dietary wisdom and underscores how much genetics shapes individual health outcomes. The research is preliminary, but the implication is significant: there may be no universal "healthy diet."
Three more quick:
61% of Americans told Gallup this week they worry "a great deal" about the availability and affordability of healthcare — the highest share in six years
The 2026 World Happiness Report flagged social media use as a primary driver of declining happiness across every demographic under 40
A Spanish woman, 25, became the youngest person in Spain to legally receive euthanasia — a case that has reignited the debate across Europe over where end-of-life rights begin and end
NexoBrief take: The Cryptotermes mobydicki deserves more coverage than it's getting. But the healthcare worry number is the one to sit with. 61% of Americans anxious about accessing basic medical care — in the world's wealthiest country — is a policy failure that predates every current crisis.
NEXOBRIEF
nexobrief.com | Free. Every weekday at 7am.
Finance, AI, Current Events, Startups — No MBA Required.
Have a great weekend. See you Monday.